Judith Blumstock

CEO and Founder

Judith Blumstock picture

Judith Blumstock

Diamond Therapeutics

CEO and Founder

Judy has over 25 years of venture capital and private equity experience spanning early to late-stage investment in life science and biotechnology. Before founding Diamond Therapeutics, Judy spent more than ten years as the executive director of corporate development for Toronto Innovation Acceleration Partners (TIAP). She held senior roles at Genesys Capital, RBC Capital Partners, and at Drug Royalty Corporation (now DRI Capital Inc.), where she served as the director of biological and pharmaceutical research. Judy brings this depth of experience to the psychedelic space as the CEO of Diamond Therapeutics. Founded in 2018, Diamond is focused on broadly accessible, low-dose psychedelic therapies for the treatment of mental health.